Radiofrequency ablation of locally advanced pancreatic adenocarcinoma: an overview

Radiofrequency ablation (RFA) of pancreatic neoplasms is restricted to locally advanced, non-resectable but non-metastatic tumors. RFA of pancreatic tumors is nowadays an ultrasound-guided procedure performed during laparotomy in open surgery. Intraoperative ultrasound covers the mandatory role of s...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 16; no. 28; pp. 3478 - 3483
Main Authors D'Onofrio, Mirko, Barbi, Emilio, Girelli, Roberto, Martone, Enrico, Gallotti, Anna, Salvia, Roberto, Martini, Paolo-Tinazzi, Bassi, Claudio, Pederzoli, Paolo, Pozzi Mucelli, Roberto
Format Journal Article
LanguageEnglish
Published United States The WJG Press and Baishideng 28.07.2010
Subjects
Adenocarcinoma - mortality
Adenocarcinoma - pathology
Adenocarcinoma - surgery
Catheter Ablation - methods
Humans
Necrosis
Pancreatic Neoplasms - mortality
Pancreatic Neoplasms - pathology
Pancreatic Neoplasms - surgery
Quality of Life
Survival Rate
Treatment Outcome
Online AccessGet full text

Cover

More Information
Summary:Radiofrequency ablation (RFA) of pancreatic neoplasms is restricted to locally advanced, non-resectable but non-metastatic tumors. RFA of pancreatic tumors is nowadays an ultrasound-guided procedure performed during laparotomy in open surgery. Intraoperative ultrasound covers the mandatory role of staging, evaluation of feasibility, guidance and monitoring of the procedure. Different types of needle can be used. The first aim in the evaluation of RFA as a treatment for locally advanced pancreatic ductal adenocarcinoma, in order of evaluation but not of importance, is to determine the feasibility of the procedure. The second aim is to establish the effect of RFA on tumoral mass in terms of necrosis and cytoreduction. The most important aim, third in order of evaluation, is the potential improvement of quality of life and survival rate. Nowadays, only a few studies assess the feasibility of the procedure. The present paper is an overview of RFA for pancreatic adenocarcinoma.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
Correspondence to: Mirko D’Onofrio, MD, Assistant Professor, Department of Radiology, University Hospital G.B. Rossi, University of Verona, Piazzale L.A. Scuro 10, Verona 37134, Italy. mirko.donofrio@univr.it
Author contributions: D’Onofrio M, Barbi E, Girelli R, Martone E, Gallotti A, Salvia R, Martini PT, Bassi C, Pederzoli P and Pozzi Mucelli R contributed equally to this work; D’Onofrio M and Gallotti A designed and performed the review; D’Onofrio M, Barbi E and Gallotti A wrote the paper; Pozzi Mucelli R revised the manuscript.
Telephone: +39-45-8124140 Fax: +39-45-8277808
ISSN:1007-9327
2219-2840
DOI:10.3748/wjg.v16.i28.3478